Alsafa & Almarwa is proud to announce a new partnership with Resono Ophthalmic, an Italian pioneer in ophthalmic therapeutic devices and the sole company in the world applying Quantum Molecular Resonance (QMR®) technology to eye care.

Through this partnership, we will bring Resono's flagship device, Rexon-Eye, to ophthalmologists and dry-eye specialists across Egypt — a non-invasive, CE-marked treatment for all forms of dry eye disease, both evaporative and hypo-secretive.

Rexon-Eye and QMR® technology:

  • Uses low-power, high-frequency electric fields (4–64 MHz) to stimulate natural cellular and tissue regeneration
  • Reactivates the lacrimal system and stimulates tear and lipid secretion through mild hyperthermia and cellular massage effects
  • Clinically shown to improve tear break-up time, meibomian gland function, and OSDI symptom scores, with benefits lasting at least two months post-treatment
  • Patented in Europe, the US, China, and other major markets, with EC certification since 2016

This partnership reflects our continued commitment to bringing clinically validated, next-generation treatment options to our partners in ophthalmology. Stay tuned for more details on availability and live demonstrations.

For inquiries, contact us at info@alsafa-almarwa.com.